As part of the ASCO Annual Meeting Education Program, three panel sessions will highlight the issue of value in cancer care and why it is an important consideration today for oncologists and their patients.
The field of palliative oncology has grown steadily for over 30 years, to the point that palliative care is now considered a standard component of modern cancer care from diagnosis through survivorship.
Quality and value are prominent topics during the 2016 ASCO Annual Meeting. Among the topics features at these sessions are practical ways to define and measure quality in the oncology practice and how to harness the power of technology to provide value to patients.
COME HOME is a community oncology medical home model using a standardized, computer-based decision support tool for first responders and triage nurses to improve health outcomes and reduce the cost of care.
A 12-week regimen of zoledronic acid is noninferior to a 4-week regimen in patients with breast cancer, prostate cancer, or multiple myeloma with bone metastases. Data on biochemical markers of bone turnover and cost effectiveness are still awaited.
Adoptive transfer of human leukocyte antigen partially matched Epstein Barr virus-specific cytotoxic T lymphocytes had limited toxicity and produced sustained responses after allogeneic hematopoietic or organ transplant.
Quality is a growing trend in oncology, but the development and facilitation of quality criteria and measurement tools of those criteria are still not widely agreed upon. Drs. Helen Burstin, Lawrence N. Shulman, and Craig Earle will present the current landscape of quality measurement in oncology.